HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders.

Abstract
We report a case of dermatomyositis associated with rheumatoid arthritis, Hashimoto thyroiditis, and diabetes mellitus responsive only to combination of rituximab with mycophenolate. A 42-year-old woman presented with proximal muscle weakness, myalgias, fever, night sweats, and shortness of breath. Creatinine kinase was 8155 IU/L, and muscle biopsy was diagnostic of dermatomyositis. She was started on glucocorticoids; her systemic symptoms improved, but her muscle weakness persisted. She was serially treated with intravenous immunoglobulin, azathioprine, and mycophenolate mofetil without improvement in her weakness. She responded dramatically to combination therapy with rituximab and mycophenolate, with improvement in strength and normalization of creatinine kinase. She has been well controlled on rituximab infusion every 6 months and maintenance mycophenolate mofetil.
AuthorsNicholas Parziale, Susan C Kovacs, Christine B Thomas, Jayashri Srinivasan
JournalJournal of clinical neuromuscular disease (J Clin Neuromuscul Dis) Vol. 13 Issue 2 Pg. 63-7 (Dec 2011) ISSN: 1537-1611 [Electronic] United States
PMID22361690 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Dermatologic Agents
  • Rituximab
  • Mycophenolic Acid
Topics
  • Adult
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • Antirheumatic Agents (administration & dosage)
  • Arthritis, Rheumatoid (complications, drug therapy)
  • Autoimmune Diseases (complications, drug therapy)
  • Dermatologic Agents (administration & dosage)
  • Dermatomyositis (complications, drug therapy)
  • Drug Therapy, Combination (methods)
  • Female
  • Hashimoto Disease (complications, drug therapy)
  • Humans
  • Mycophenolic Acid (administration & dosage, analogs & derivatives)
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: